Key result
Serum cystatin C demonstrated higher diagnostic accuracy (98.33% vs 85%) and a stronger correlation with DTPA-GFR (r=0.78 vs r=0.59) compared to serum creatinine for predicting early renal impairment in diabetic patients.
Why the study?
Does eGFR based on serum cystatin C improve the prediction of renal function compared to eGFR based on serum creatinine in diabetic patients?
Cross-Sectional (n=60)
No
Does eGFR based on serum cystatin C improve the prediction of renal function compared to eGFR based on serum creatinine in diabetic patients?
Effect estimate: r=0.78
Absolute Event Rate: 0.78% vs 0.59%
p-value: p=<0.001
Serum cystatin C is a more accurate and sensitive biomarker than serum creatinine for the early detection of renal impairment in diabetic patients.
Cystatin C may aid earlier detection in diabetes; leaves open whether cystatin-based eGFR should replace creatinine-based estimates in practice.
Serum cystatin C is a new promising marker of renal function. The aim of this study was to analyze serum cystatin C as a better predictor of renal function in diabetic nephropathy. In 60 diagnosed diabetic patients, serum cystatin C and serum creatinine were assessed. Glomerular filtration rate was estimated based on the cystatin C concentration according to Cockcroft- Gault formula and based on serum creatinine concentration according to Larsson formula. DTPA-GFR (Diethylenetriamene pentaacetate Renogram) was done as reference standard. The cross tabulation of DTPA-GFR was done with eGFR- creatinine and eGFRcystatin C. The calculated sensitivity, specificity and accuracy of eGFR- creatinine were 85%, 87.2% and 85% respectively. The eGFR- cystatin C showed higher sensitivity, specificity and accuracy than eGFR- creatinine in studied diabetic subjects. The cystatin C showed more significant correlation, r=0.78, p<0.001 than serum creatinine, r=0.59, p<0.001 with DTPA-GFR in diabetic patients. This study demonstrates that serum cystatin C may be used for early prediction for renal function impairment in diabetic kidney disease. DOI: http://dx.doi.org/10.3329/bjmb.v4i1.13777 Bangladesh J Med Biochem 2011; 4(1): 16-20
No takes yet. Share an insight, caveat, or question.
Shima et al. (2013) conducted a cross-sectional in Diabetic nephropathy (n=60). Serum cystatin C vs. Serum creatinine was evaluated on Correlation with DTPA-GFR (r=0.78, p=<0.001). Serum cystatin C demonstrated higher diagnostic accuracy (98.33% vs 85%) and a stronger correlation with DTPA-GFR (r=0.78 vs r=0.59) compared to serum creatinine for predicting early renal impairment in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: